Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Prime Medicine Inc (NQ: PRME ) 3.460 -0.100 (-2.81%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Prime Medicine Inc < Previous 1 2 Next > Prime Medicine to Participate in Upcoming Investor Conferences August 28, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates August 08, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Upcoming Investor Conferences May 30, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 13, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates May 10, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) May 08, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference May 01, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) April 29, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings April 23, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates March 01, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Participate in Upcoming Investor Conferences February 28, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares February 20, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Announces Pricing of Upsized Public Offering February 14, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Announces Proposed Public Offering of Common Stock February 14, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis January 25, 2024 From Prime Medicine, Inc. Via GlobeNewswire 2 gene editing stocks to keep on your 2024 watchlist January 23, 2024 Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Via MarketBeat Exposures Product Safety Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer January 05, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Upcoming Investor Conferences November 08, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates November 03, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b October 27, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases October 24, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences October 17, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Upcoming Investor Conferences September 19, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Upcoming Investor Conferences August 31, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates August 07, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome June 22, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Investor Conferences in June May 31, 2023 From Prime Medicine, Inc. Via GlobeNewswire Prime Medicine to Present at Virtual Investor Conferences in May May 17, 2023 From Prime Medicine, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.